Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Patent litigation with Teva resolved for all LYBALVI dosage strengths through a settlement and license agreement.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Patent litigation with Teva resolved for all LYBALVI dosage strengths through a settlement and license agreement
- Teva’s U.S. generic entry permitted beginning November 12, 2039, or May 12, 2040 with pediatric exclusivity
- Earlier entry remains possible under certain settlement conditions, creating long-term generic competition risk
- Pending New Jersey infringement proceedings dismissed with prejudice, subject to FTC and DOJ review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.